<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Nyt GSK studie med ofatumumab (nr. 55), http:&#x2F;&#x2F;clinicaltrials.gov&#x2F;ct2&#x2F;show&#x2F;NCT01313689?term=ofatumumab&amp;rank=26]]></title><description><![CDATA[<p dir="auto">Nyt GSK studie med ofatumumab (nr. 55), <a href="http://clinicaltrials.gov/ct2/show/NCT01313689?term=ofatumumab&amp;rank=26" rel="nofollow ugc">http://clinicaltrials.gov/ct2/show/NCT01313689?term=ofatumumab&amp;rank=26</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/448362/nyt-gsk-studie-med-ofatumumab-nr-55-httpclinicaltrialsgovct2shownct01313689termofatumumabrank26</link><generator>RSS for Node</generator><lastBuildDate>Sat, 20 Jun 2026 10:25:29 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/448362.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 17 Mar 2011 21:51:19 GMT</pubDate><ttl>60</ttl></channel></rss>